ELAN

Elanco Animal Health (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Elanco Animal Health has quietly turned into a strong performer over the past few years, which naturally puts today’s share price under the microscope.

Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Elanco (NYSE:ELAN) and the best and worst performers in the pharmaceuticals industry.

* New report shows warmer fall, later freeze and a longer allergy season across the country.i * Seasonal allergies increase the risk of itchy dogs, and nearly 9 in 10 dogs in the U.

Purpose-built research, incubator and laboratory space will leverage Purdue's R1 capabilities and 's animal health leadership to advance One Health innovation in IndianapolisINDIANAPOLIS, IN / ACCESS Newswire / October 7, 2026 / The One Health Innovation…

Elanco Animal Health (NYSE:ELAN) President and CEO Jeff Simmons outlined the company’s growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London.

Elanco currently trades at $23.15 per share and has shown little upside over the past six months, posting a small loss of 1.1%. The stock also fell short of the S&P 500’s 14.2% gain during that period.

Innovation that protects against these pests is driving stronger Elanco base business and overall share gains. Elanco confirms U.S. Pet Health is on track to expectations of high-single digit to low double-digit growth in the second half of 2026. U.S.